At InterveXion we develop novel products for the treatment of addiction disorders. Since our founding in 2004, our team has been dedicated to providing therapeutic options for patients suffering from the debilitating effects of addiction. We occupy office and laboratory space in the BioVentures Building on the campus of the University of Arkansas for Medical Sciences (UAMS), from whom we licensed our lead technology.
Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine. IXT-m200 represents a unique approach in addiction medicine – rather than trying to identify and block sites of action of methamphetamine in the brain, we bind methamphetamine in the blood to decrease brain penetration. This approach underlies all our programs, and has been recognized by the National Institute on Drug Abuse (NIDA) in their strategic plan, and NIDA has provided significant funding for our development programs to date.
IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). In the STAMPOUT study, we are studying the effect of IXT-m200 on the pharmacokinetics and pharmacodynamics of methamphetamine in non-treatment seeking methamphetamine users. If successful, we plan to advance IXT-m200 into a Phase 2b/3 study in treatment-seeking methamphetamine users which could support registration.
In addition to our lead antibody program, we are also developing a novel vaccine (IXT-v100) against methamphetamine. The vaccine works using the same principles as the antibody, but is anticipated to be longer-acting and be administered via a simple intramuscular injection. IXT-v100 is currently in late Preclinical Development.
Finally, InterveXion is also interested in identifying collaborations and licensing opportunities in the area of drug abuse and addiction to add to our pipeline in the future, and we encourage interested parties to contact us for such discussions.